Increasing Burden of Cardiovascular Disease
- 24 March 1998
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 97 (11) , 1095-1102
- https://doi.org/10.1161/01.cir.97.11.1095
Abstract
Lewis A. Conner was the first president of the American Heart Association and founding editor of the American Heart Journal . In the inaugural issue of that journal, in October 1925, Dr Conner wrote that the “newly awakened interest in disorders of the cardiovascular system” has rapidly led to the recognition of heart disease as a significant public health problem that “can no longer be disregarded.”1 In the ensuing years, the United States first experienced a 40-year increasing epidemic of cardiovascular disease, followed by remarkable gains in prevention and treatment that led to a dramatic 30-year decline in mortality from coronary heart disease (CHD) and stroke. At present, however, heart disease remains far and away the leading cause of mortality in the United States, responsible for about one of every three deaths. Stroke accounts for 6% to 7% of all deaths, so overall cardiovascular disease remains responsible for about 40% of all US deaths.2 Further gains in the prevention and treatment of cardiovascular disease will require concerted efforts—and the necessary allocation of resources—on at least two major fronts. First, public policy and health efforts must vigorously promote those measures in prevention and treatment for which abundant evidence of clear benefits already exists. Second, funding must be provided for current research to evaluate new possible preventive and therapeutic interventions and to expand frontiers in genetic, thrombotic, atherogenic, and inflammatory markers of cardiovascular disease risk. Advances in knowledge proceed on several fronts, optimally simultaneously. Basic researchers provide biological mechanisms and answer the crucial question of why an agent or intervention reduces premature death. Clinicians are providing enormous benefits to affected patients through advances in diagnosis and treatment and formulate hypotheses from their clinical experiences in case reports and case series. Clinical investigators address the relevance of basic research findings to …This publication has 45 references indexed in Scilit:
- Effects of a Combination of Beta Carotene and Vitamin A on Lung Cancer and Cardiovascular DiseaseNew England Journal of Medicine, 1996
- Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.Journal of Clinical Investigation, 1995
- Effect of High-Dose Ibuprofen in Patients with Cystic FibrosisNew England Journal of Medicine, 1995
- Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees.The Journal of Experimental Medicine, 1994
- Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)The American Journal of Cardiology, 1993
- Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution biasPublished by Elsevier ,1990
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988
- Fibrinogen as a Risk Factor for Stroke and Myocardial InfarctionNew England Journal of Medicine, 1984
- The American Heart JournalAmerican Heart Journal, 1925